SPC166
Elótúsúmab í samsetningu með lenalídómíði & dexametasóni
Status:
VeittApplication date:
1.11.2016Application published:
15.11.2016Grant published:
15.12.2019
Max expiry date:
12.5.2031Medicine name:
EmplicitiMedicine for children:
No
Timeline
Today
1.11.2016Application
15.11.2016Publication
15.12.2019Registration
12.5.2031Expires
Marketing license
IS authorization number:
EU/1/16/1088/001-002Date:
2.3.2018
Foreign authorization number:
EU/1/16/1088Date:
19.5.2016
Owner
Name:
AbbVie Biotherapeutics Inc.Address:
1500 Seaport Boulevard, Redwood City, CA US
Name:
Dana-Farber Cancer Institute, Inc.Address:
450 Brookline Avenue, Boston, MA US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113 Reykjavík
Patent
Number:
EP2068874